GSK, Hansoh Pharma ink pact for HS-20089
Under the terms of this agreement, GSK will pay an USD 85 million upfront payment.
London: GSK plc and Hansoh Pharma have announced that they have entered into an exclusive license agreement for HS-20089, a B7-H4 targeted antibody-drug conjugate (ADC) currently in phase I (NCT05263479) clinical trials in China. Under the agreement, GSK will obtain exclusive worldwide rights (excluding China’s mainland, Hong Kong, Macau, and Taiwan) to progress development and commercialisation of HS-20089.
Hesham Abdullah, SVP, Global Head Oncology, R&D, GSK, said, “Given early clinical data, we believe that HS-20089 has best-in-class potential in ovarian and endometrial cancer with opportunities in other solid tumours. This agreement is in line with our approach to advancing novel treatment options for patients with gynaecologic cancers.”
In addition to targeting the B7-H4 surface antigen, which is overexpressed in ovarian and endometrial cancers and is often associated with poor prognosis, HS-20089 utilises clinically validated ADC technologies such as a topoisomerase inhibitor (TOPOi) payload. TOPOi is a validated mechanism of action in approved anti-cancer medicines and a proven standard of care in the treatment of breast and ovarian cancers.
Eliza Sun，Executive Director of Board, Hansoh Pharma, said, “In line with our commitment to deliver first- or best-in-class medicines to address unmet medical needs, Hansoh is excited to explore further development of HS-20089 to bring breakthrough medicines to cancer patients. GSK’s R&D expertise and commercial footprint in developing therapies for gynaecologic cancers make them the ideal licensee to bring HS-20089 to patients outside of China.”
"This agreement builds on GSK’s strategic R&D focus on tumour-cell targeting modalities as well as expertise in gynaecologic cancers including a significant medical and commercial presence," the release stated.
HS-20089 complements GSK’s oncology portfolio and strategic disease area focus, including potential future combinations.
GSK plans to begin phase I trials outside of China in 2024.
Under the terms of this agreement, GSK will pay an $85 million upfront payment. In addition, Hansoh will be eligible to receive up to $1.485 billion in success-based milestones for HS-20089. Upon commercialisation of HS-20089, GSK will also pay tiered royalties on global net sales outside of China’s mainland, Hong Kong, Macau, and Taiwan.
This agreement is subject to appropriate regulatory agency clearances, including under the Hart-Scott-Rodino Act in the US.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.